Understanding the persistence of gonococci and the evolution of antimicrobial resistance (AMR) is critical for the successful control of gonorrhea. gonorrhoeae does not produce exotoxins, it can damage host cells by releasing toxin molecules, such as lipo-oligosaccharides and peptidoglycan fragments. Neisseria gonorrhoeae is the only member of the Neisseria genus that parasitizes the human reproductive tract and annually causes an estimated 108 million cases globally. Keywords: Neisseria gonorrhoeae, pathogenicity islands, drug resistance, TRNG, MLST
These four types are more likely to become highly virulent strains. gonorrhoeae typed as ST1928, ST1901, ST1588 and ST7822, the GGI were all positive. Among the 37 isolates studied, 12 distinct MLST were determined, while MLST ST8123 occurred most frequently, accounting for 18.91% (7/37), followed by ST1928, ST7367 and ST7822, all 13.51% (5/37).Ĭonclusion: N.
No significant difference in the positive rate of the GGI between the azithromycin-sensitive and the resistance groups or between the β-lactam positive and negative groups ( P > 0.05) was found however, there was a significant difference between the high-level tetracycline-resistant group and the non-high-level resistant group (P < 0.05), with the carrier rates being 60.00% and 94.45%, respectively. In this study, atlA, traG and traH were always detected positive together. gonorrhoeae were widespread, and the positive detection rates of atlA, traG and traH were all 81.08% (30/37). All clinical isolates were subjected to N.
Genes in GGI ( atlA, traG, and traH) were amplified via polymerase chain reaction (PCR). Resistance to tetracycline, β-lactam, and azithromycin were measured. Methods: From January 2018 to December 2020, a total of 37 clinical isolates of N. gonorrhoeae genetic island (GGI), and to understand the existence of GGI of different multilocus sequence types (MLST), so as to provide evidence for epidemiology. Purpose: To investigate the carrying situation of N. *These authors contributed equally to this workĬorrespondence: Zhou Zheng, Email Dan Zhang 1 *, Mingpeng Hu 2 *, Shengying Chi, 1 Han Chen, 1 Chunchan Lin, 1 Fangyou Yu, 3 Zhou Zheng 1ġDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China 2Ruian Traditional Chinese Medicine Hospital, Wenzhou, People’s Republic of China 3Department of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
0 kommentar(er)
